[go: up one dir, main page]

WO2019126364A3 - Compositions et méthodes se rapportant à la dépendance à la nicotine et à l'arrêt de celle-ci - Google Patents

Compositions et méthodes se rapportant à la dépendance à la nicotine et à l'arrêt de celle-ci Download PDF

Info

Publication number
WO2019126364A3
WO2019126364A3 PCT/US2018/066562 US2018066562W WO2019126364A3 WO 2019126364 A3 WO2019126364 A3 WO 2019126364A3 US 2018066562 W US2018066562 W US 2018066562W WO 2019126364 A3 WO2019126364 A3 WO 2019126364A3
Authority
WO
WIPO (PCT)
Prior art keywords
nicotine
cessation
compositions
nicotine addiction
methods related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/066562
Other languages
English (en)
Other versions
WO2019126364A2 (fr
Inventor
Kim D. Janda
Olivier GEORGE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of WO2019126364A2 publication Critical patent/WO2019126364A2/fr
Publication of WO2019126364A3 publication Critical patent/WO2019126364A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01328—Nicotine blue oxidoreductase (1.1.1.328)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des enzymes de fusion dégradant la nicotine qui sont constituées d'une enzyme dégradant la nicotine tronquée N-terminale (par exemple NicA2) et d'un partenaire de fusion (par exemple, une fraction de liaison à l'albumine). L'invention concerne également des méthodes thérapeutiques d'utilisation des enzymes de fusion pour favoriser l'arrêt de la nicotine, traiter la dépendance à la nicotine ou l'empoisonnement par la nicotine, et empêcher une rechute.
PCT/US2018/066562 2017-12-19 2018-12-19 Compositions et méthodes se rapportant à la dépendance à la nicotine et à l'arrêt de celle-ci Ceased WO2019126364A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762607423P 2017-12-19 2017-12-19
US62/607,423 2017-12-19
US201862765355P 2018-08-20 2018-08-20
US62/765,355 2018-08-20

Publications (2)

Publication Number Publication Date
WO2019126364A2 WO2019126364A2 (fr) 2019-06-27
WO2019126364A3 true WO2019126364A3 (fr) 2020-03-26

Family

ID=66993906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/066562 Ceased WO2019126364A2 (fr) 2017-12-19 2018-12-19 Compositions et méthodes se rapportant à la dépendance à la nicotine et à l'arrêt de celle-ci

Country Status (1)

Country Link
WO (1) WO2019126364A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019015788A2 (pt) 2017-02-03 2020-03-17 Antidote Therapeutics, Inc. Variantes inovadoras de enzima de degradação de nicotina
JP2021532761A (ja) 2018-08-02 2021-12-02 アンティドートゥ・セラピューティクス・インコーポレイテッド 新規ニコチン分解酵素変異体

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150291668A1 (en) * 2012-10-25 2015-10-15 Affibody Ab Abd binding polypeptide
WO2017023904A2 (fr) * 2015-08-04 2017-02-09 The Scripps Research Institute Enzymes de dégradation de la nicotine pour le traitement d'une dépendance à la nicotine et d'un empoisonnement à la nicotine
WO2017167250A1 (fr) * 2016-04-01 2017-10-05 上海交通大学 Enzyme et son application
WO2018144879A1 (fr) * 2017-02-03 2018-08-09 Antidote Therapeutics, Inc. Nouveaux variants d'enzyme dégradant la nicotine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150291668A1 (en) * 2012-10-25 2015-10-15 Affibody Ab Abd binding polypeptide
WO2017023904A2 (fr) * 2015-08-04 2017-02-09 The Scripps Research Institute Enzymes de dégradation de la nicotine pour le traitement d'une dépendance à la nicotine et d'un empoisonnement à la nicotine
US20190015484A1 (en) * 2015-08-04 2019-01-17 The Scripps Research Institute Nicotine-degrading enzymes for treating nicotine addiction and nicotine poisoning
WO2017167250A1 (fr) * 2016-04-01 2017-10-05 上海交通大学 Enzyme et son application
WO2018144879A1 (fr) * 2017-02-03 2018-08-09 Antidote Therapeutics, Inc. Nouveaux variants d'enzyme dégradant la nicotine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MCCLURE, EA ET AL.: "An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers", AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, vol. 41, no. 1, January 2015 (2015-01-01), pages 52 - 56 *
PENTEL, PR ET AL.: "The nicotine-degrading enzyme NicA2 reduces nicotine levels in blood, nicotine distribution to brain, and nicotine discrimination and reinforcement in rats", BMC BIOTECHNOLOGY, vol. 18, no. 46, 24 July 2018 (2018-07-24), pages 1 - 14, XP055694589 *
TARARINA, MA ET AL.: "Structural Analysis Provides Mechanistic Insight into Nicotine Oxidoreductase from Pseudomonas putida", BIOCHEMISTRY, vol. 55, no. 48, 6 December 2016 (2016-12-06), pages 6595 - 6598, XP055467672, DOI: 10.1021/acs.biochem.6b00963 *
XUE, S ET AL.: "An Enzymatic Advance in Nicotine Cessation Therapy", CHEMICAL COMMUNICATIONS, vol. 54, no. 14, 13 February 2018 (2018-02-13), pages 1686 - 1689, XP055694590 *

Also Published As

Publication number Publication date
WO2019126364A2 (fr) 2019-06-27

Similar Documents

Publication Publication Date Title
PH12020551997A1 (en) Psma binding agents and uses thereof
WO2020039321A8 (fr) Anticorps anti-gdf15, compositions et procédés d'utilisation
MX2022010490A (es) Composiciones utiles para enzimas de internalizacion.
EP3835322A3 (fr) Anticorps anti-b7-h3 et conjugués anticorps-médicament
WO2019241430A3 (fr) Conjugués anticorps-oligonucléotide
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
WO2007115837A3 (fr) Combinaison d'une protéine de fusion à anticorps anti-domaine ed-b de fibronectine et à il-2, et de gemcitabine
WO2018151821A8 (fr) Anticorps anti-alpha-synucléine et leurs utilisations
WO2020172631A3 (fr) Protéines de fusion fc d'il-10 non ciblées et ciblées
MX2022009302A (es) Compuestos de unión a il-7r¿.
EP4527466A3 (fr) Récepteurs antigéniques chimériques anti-dll3 et leurs utilisations
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
ATE518010T1 (de) Aktive oberflächengekoppelte polymerasen
EP4372002A3 (fr) Purification et ligature de protéines médiées par la sortase à base de proximité
AU2018337947A1 (en) Compositions and methods for predicting response to NaPi2b-targeted therapy
MX2023014458A (es) Anticuerpos anti-ccr8 y usos de los mismos.
MX2019009541A (es) Proteinas que se unen a psma, nkg2d y cd16.
MX2022013938A (es) Etiquetas peptidicas y parejas de union.
SA523451582B1 (ar) Ccr8 الأجسام المضادة لـ
WO2017023904A3 (fr) Enzymes de dégradation de la nicotine pour le traitement d'une dépendance à la nicotine et d'un empoisonnement à la nicotine
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
MX2021006515A (es) Composiciones de methylobacterium para mejorar el rendimiento del maíz.
WO2021207433A3 (fr) Épitopes d'anticorps neutralisant le sars-cov-2
PH12021551422A1 (en) Anti-il-36 antibodies and methods of use thereof
WO2007146813A3 (fr) Analogues de pyridinone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18890810

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18890810

Country of ref document: EP

Kind code of ref document: A2